Related Experiment Video
Updated: Dec 12, 2025
Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians
Published on: March 14, 2014
Adequate duration of therapy in severe fungal infections
Matteo Bassetti1,2, Daniele R Giacobbe1, Marco Berruti1
1Infectious Diseases Unit, Ospedale Policlinico San Martino - IRCCS.
Purpose Of Review:
To highlight recent findings on the adequate duration of antifungal therapy in patients with invasive fungal disease (IFD).
Recent Findings:
Plenty of published data available suggest that there is no additional clinical benefit at a certain point after initiation of antifungal treatment in patients with confirmed IFD. Moreover, the prolonged antifungal exposure can be associated with an increased risk of side effects and toxicity as well as striking risk for developing antifungal resistance or rising unnecessary healthcare costs. Recent data suggest that, in the presence of an adequate initial antifungal therapy and adequate source control of the infection, new stratified approaches integrating clinical judgment, biomarkers and microbiological eradication, should be considered as an alternative to the 'one-size-fits-all' treatment duration currently used worldwide.
Summary:
The optimal duration of antifungal therapy is still an unresolved issue that depends by many key elements including the host; the pathogen and its microbiological eradication, the adequateness of initial antifungal therapy and the promptness of source control of the infection. In general, many patients with invasive candidiasis can be treated with a 2 weeks course of antifungal therapy. Longer antifungal course (6 weeks or more) is generally required for patients with invasive aspergilosis.
Insights
Determining the optimal duration for antifungal therapy in invasive fungal disease (IFD) is crucial. Recent findings suggest personalized approaches may be more effective than standard durations, reducing risks and costs.
Area of Science:
- Mycology
- Infectious Diseases
- Clinical Pharmacology
Background:
- Invasive fungal disease (IFD) management requires careful consideration of antifungal therapy duration.
- Prolonged treatment increases risks of toxicity, resistance, and healthcare costs without clear clinical benefit.
Purpose of the Study:
- To review recent findings on the appropriate duration of antifungal therapy for patients with IFD.
- To explore alternative treatment strategies beyond the standard 'one-size-fits-all' approach.
Main Methods:
- Review of published data and recent findings on antifungal therapy duration.
- Analysis of factors influencing treatment outcomes, including host, pathogen, and source control.
- Evaluation of stratified approaches integrating clinical judgment, biomarkers, and microbiological eradication.
Main Results:
- Evidence suggests no additional clinical benefit beyond a certain point in antifungal treatment for IFD.
- Personalized, stratified approaches are emerging as alternatives to fixed-duration therapy.
- Specific durations vary; invasive candidiasis may require 2 weeks, while invasive aspergillosis may need 6 weeks or more.
Conclusions:
- Optimal antifungal therapy duration is multifactorial, depending on host, pathogen, and treatment adequacy.
- Stratified approaches integrating clinical factors offer a promising alternative to current standard durations.
- Tailoring antifungal therapy duration can optimize outcomes and minimize adverse effects.
Related Concept Videos
01:28Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
01:28Fungal Phylum Microsporidia
01:15Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
01:18Endocarditis III: Medical Management
01:28Acute Pyelonephritis II: Diagnostic Studies and Management